MARKET

ORGO

ORGO

Organogenesis Holdings Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.41
+0.09
+0.59%
Closed 16:00 07/29 EDT
OPEN
15.39
PREV CLOSE
15.32
HIGH
15.64
LOW
15.23
VOLUME
515.06K
TURNOVER
--
52 WEEK HIGH
24.34
52 WEEK LOW
3.360
MARKET CAP
1.98B
P/E (TTM)
42.91
1D
5D
1M
3M
1Y
5Y
Organogenesis Holdings (NASDAQ:ORGO) Seems To Use Debt Quite Sensibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Simply Wall St. · 3d ago
Organogenesis Holdings Inc (ORGO) President and CEO Gary S. Gillheeney Sold $4.3 million of Shares
GuruFocus News · 07/21 05:22
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2021 Financial Results on August 9, 2021
CANTON, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgica...
GlobeNewswire · 07/02 11:30
Organogenesis Holdings Insights: Return On Capital Employed
Organogenesis Holdings (NASDAQ:ORGO) posted Q1 earnings of $12.62 million, an increase from Q4 of 42.05%. Sales dropped to $102.55 million, a 3.98% decrease between quarters. In Q4, Organogenesis Holdings earned $21.77 million, and total sales reached $106...
Benzinga · 06/24 13:51
Estimating The Fair Value Of Organogenesis Holdings Inc. (NASDAQ:ORGO)
In this article we are going to estimate the intrinsic value of Organogenesis Holdings Inc. ( NASDAQ:ORGO ) by...
Simply Wall St. · 06/18 08:02
Looking Into Organogenesis Holdings's Return On Capital Employed
Looking at Q1, Organogenesis Holdings (NASDAQ:ORGO) earned $12.62 million, a 42.05% increase from the preceding quarter. Organogenesis Holdings's sales decreased to $102.55 million, a 3.98% change since Q4. Organogenesis Holdings earned $21.77 million, and...
Benzinga · 06/08 15:38
Organogenesis (ORGO) Stock Jumps 7.7%: Will It Continue to Soar?
Organogenesis (ORGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Zacks · 05/28 13:03
60 Biggest Movers From Yesterday
Gainers Vertex Energy, Inc. (NASDAQ: VTNR) shares climbed 124.2% to settle at $3.99 on Thursday after the company announced plans to acquire a Alabama refinery and related logistics assets.
Benzinga · 05/28 09:28
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ORGO. Analyze the recent business situations of Organogenesis Holdings Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ORGO stock price target is 26.25 with a high estimate of 28.00 and a low estimate of 24.00.
EPS
Institutional Holdings
Institutions: 113
Institutional Holdings: 24.95M
% Owned: 19.46%
Shares Outstanding: 128.22M
TypeInstitutionsShares
Increased
34
5.43M
New
39
6.42M
Decreased
18
7.95M
Sold Out
6
395.46K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.26%
Pharmaceuticals & Medical Research
-0.31%
Key Executives
President/Chief Executive Officer/Director
Gary Gillheeney
Chief Financial Officer
David Francisco
Chief Operating Officer
Patrick Bilbo
Vice President/General Counsel
Lori Freedman
Vice President
Antonio Montecalvo
Other
Brian Grow
Director
Robert Ades
Director
David Erani
Director
Jon Giacomin
Director
Glenn Nussdorf
Independent Director
Alan Ades
Independent Director
Arthur Leibowitz
Independent Director
Wayne Mackie
No Data
  • All
  • Financials
  • Insiders
More
About ORGO
Organogenesis Holdings Inc., formerly Avista Healthcare Public Acquisition Corp, is a regenerative medicine company. The Company focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. It also provides integrated healing solutions that substantially improve medical outcomes. The Company’s advanced wound care and surgical & sports medicine products include PuraPly, Antimicrobial (PuraPlyAM), PuraPly, Affinity, NuShield, Apligraf and Dermagraft. The Company is offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. The Company’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs.

Webull offers kinds of Organogenesis Holdings Inc stock information, including NASDAQ:ORGO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORGO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ORGO stock methods without spending real money on the virtual paper trading platform.